CD4 and hepatocellular carcinoma: Although SP16 treatment restored the depleted CD4+ T cells, the drug was administered late in the course of NAFLD and was therefore unable to fully modulate the hepatic immunological patterns, which appears to be critical in preventing NAFLD-associated HCC.